Elevated Carboxypeptidase B1 levels identified as potential uremic toxin among chronic kidney disease patients undergoing dialysis.
The study measured concentrations of Carboxypeptidase B1 (CPB1) in dialyzed chronic kidney disease patients and assessed the impact of dialysis adequacy and regimen on these levels.
The research was conducted by Matej Stančík, Marian Grendár, and Marian Mokáň from the University Hospital in Martin, Slovakia.
The study was published on May 1, 2025.
The research was conducted at the University Hospital in Martin, Slovakia.
Chronic kidney disease (CKD) G5d patients face cardiovascular complications, and CPB1 might contribute to uremic toxicity related to these issues.
Plasma CPB1 concentrations were assessed using ELISA across two measurements one month apart for the target group, involving 142 subjects total—111 control patients and 31 dialyzed CKD patients.
CPB1 was historically known as pancreas-specific but is now investigated for broader physiological roles, particularly concerning inflammation and chronic kidney disease.
"Measurement of plasma Carboxypeptidase B1 concentration revealed significantly higher levels among patients with end-stage renal disease compared to healthy controls."
"Our findings suggest CPB1's elevation could be indicative of novel inflammatory pathways connected with chronic kidney disease."
"Dialysis regimen significantly predicted CPB1 levels, with twice-weekly dialysis associated with higher concentrations than thrice-weekly treatments."
This study highlights the presence of elevated CPB1 levels as potential indicators of chronic inflammation contributing to complications faced by CKD patients. Research findings indicate the necessity for considering CPB1 concentrations during clinical assessments, particularly concerning dialysis regimens.
Further investigation is imperative to develop therapies targeting CPB1 pathways, as they may ameliorate inflammation and improve the health outcomes of patients with chronic kidney disease.